{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:53:18Z","timestamp":1785462798866,"version":"3.56.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korean government","award":["NRF-2021R1F1A1052976"],"award-info":[{"award-number":["NRF-2021R1F1A1052976"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is a growing health concern with increasing prevalence and associated health impacts. Although no approved drugs are available for the NAFLD treatment, several hypoglycemic agents have been investigated as promising therapeutic agents. We aimed to compare the risk of occurrence of NAFLD with respect to the use of different hypoglycemic agents in patients with type 2 diabetes. This retrospective cohort study used data from the National Health Insurance Service\u2013National Sample Cohort of South Korea. Participants newly diagnosed with type 2 diabetes (2003\u20132019) were included in this study. Two new user-active comparator cohorts were assembled: Cohort 1, new users of thiazolidinediones (TZD) and dipeptidyl peptidase-4 inhibitors (DPP-4i), and Cohort 2, new users of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and DPP-4i. The occurrence of NAFLD was defined based claims that include diagnostic codes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models in 1:3 propensity score (PS)-matched cohorts. For 65,224 patients newly diagnosed with type 2 diabetes, the overall prevalence of NAFLD was 42.6%. The PS-matched Cohort 1 included 6,351 and 2,117 new users of DPP-4i and TZD, respectively. Compared to DPP-4i, TZD use was associated with the decreased risk of NAFLD (HR, 0.66; 95% CI: 0.55\u20130.78). Cohort 2 consisted of 6,783 and 2,261 new users of DPP-4i and SGLT-2i, respectively; SGLT-2i use was associated with a decreased risk of NAFLD (HR, 0.93; 95% CI: 0.80\u20131.08). This population-based cohort study supports the clinical implications of prioritizing TZD and SGLT-2i over DPP-4i in reducing the risk of occurrence of NAFLD in patients with type 2 diabetes. However, the findings lacked statistical significance, highlighting the need for further verification studies.<\/jats:p>","DOI":"10.1371\/journal.pone.0294423","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:32:31Z","timestamp":1700677951000},"page":"e0294423","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-5893","authenticated-orcid":true,"given":"Choungwon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-9787","authenticated-orcid":true,"given":"Soyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-2040","authenticated-orcid":true,"given":"Hyunah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"1","key":"pone.0294423.ref001","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0294423.ref002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes.","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology."},{"issue":"1","key":"pone.0294423.ref003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"key":"pone.0294423.ref004","author":"National interest disease statistics","journal-title":"Health Insurance Review & Assessment Service (KR)"},{"key":"pone.0294423.ref005","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111","author":"A Mantovani","year":"2020","journal-title":"Metabolism"},{"issue":"8","key":"pone.0294423.ref006","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"JM Hazlehurst","year":"2016","journal-title":"Metabolism"},{"issue":"1\u20132","key":"pone.0294423.ref007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mce.2013.06.002","article-title":"Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease","volume":"379","author":"C Koliaki","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"pone.0294423.ref008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.","volume":"53","author":"J Kumar","year":"2021","journal-title":"Digestive and Liver Disease"},{"key":"pone.0294423.ref009","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.","volume":"55","author":"G Musso","year":"2012","journal-title":"Diabetologia"},{"issue":"11","key":"pone.0294423.ref010","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long\u2010term outcome of SGLT 2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"T Arai","year":"2022","journal-title":"Hepatology Communications"},{"key":"pone.0294423.ref011","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/DMSO.S212715","article-title":"SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions","author":"NE Gharaibeh","year":"2019","journal-title":"Diabetes, metabolic syndrome and obesity: targets and therapy."},{"issue":"4","key":"pone.0294423.ref012","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2","volume":"45","author":"R Pradhan","year":"2022","journal-title":"Diabetes. Diabetes Care"},{"issue":"5","key":"pone.0294423.ref013","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/hep.32012","article-title":"Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study","volume":"74","author":"J van Dalem","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"pone.0294423.ref014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","volume":"55","author":"JA Dougherty","year":"2021","journal-title":"Annals of Pharmacotherapy"},{"issue":"2","key":"pone.0294423.ref015","article-title":"Cohort Profile: The National Health Insurance Service\u2013National Sample Cohort (NHIS-NSC), South Korea.","volume":"46","author":"J Lee","year":"2016","journal-title":"International Journal of Epidemiology"},{"issue":"9","key":"pone.0294423.ref016","doi-asserted-by":"crossref","first-page":"e0275393","DOI":"10.1371\/journal.pone.0275393","article-title":"Body mass index and stroke risk among patients with diabetes mellitus","volume":"17","author":"DK Song","year":"2022","journal-title":"Korea. Plos one"},{"issue":"3","key":"pone.0294423.ref017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.","volume":"46","author":"PC Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"6","key":"pone.0294423.ref018","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Z Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"pone.0294423.ref019","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3350\/cmh.2013.19.3.266","article-title":"Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea.","volume":"19","author":"EH Jeong","year":"2013","journal-title":"Clin Mol Hepatol."},{"key":"pone.0294423.ref020","first-page":"165","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial","author":"K Cusi","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"pone.0294423.ref021","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"GP Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0294423.ref022","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"K Promrat","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"pone.0294423.ref023","first-page":"67","article-title":"Adherence and persistence with DPP-4 inhibitors versus pioglitazone in type 2 diabetes patients with chronic kidney disease: a retrospective claims database analysis. Journal of Managed Care &","volume":"26","author":"D Gor","year":"2020","journal-title":"Specialty Pharmacy"},{"issue":"3","key":"pone.0294423.ref024","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"J Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0294423.ref025","first-page":"105","article-title":"Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis","author":"Y Zhou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0294423.ref026","first-page":"437","article-title":"The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2","author":"M Dong","year":"2023","journal-title":"Diabetes Mellitus. Diabetes"},{"issue":"12","key":"pone.0294423.ref027","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms.","volume":"19","author":"PC Lee","year":"2018","journal-title":"Obes Rev."},{"issue":"5","key":"pone.0294423.ref028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"JH Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0294423.ref029","first-page":"101","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!","author":"G Ranjbar","year":"2019","journal-title":"Metabolism-Clinical and Experimental."},{"issue":"8","key":"pone.0294423.ref030","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial).","volume":"41","author":"MS Kuchay","year":"2018","journal-title":"Diabetes care"},{"key":"pone.0294423.ref031","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"JW Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"pone.0294423.ref032","doi-asserted-by":"crossref","first-page":"e3350","DOI":"10.1002\/dmrr.3350","article-title":"Poor adherence and persistence to sodium glucose co\u2010transporter 2 inhibitors in real\u2010world settings: Evidence from a systematic review and meta\u2010analysis","volume":"37","author":"R Ofori\u2010Asenso","year":"2021","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"pone.0294423.ref033","doi-asserted-by":"crossref","first-page":"113331","DOI":"10.1016\/j.biopha.2022.113331","article-title":"Recent advances in lean NAFLD.","volume":"153","author":"R Xu","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"pone.0294423.ref034","doi-asserted-by":"crossref","first-page":"110187","DOI":"10.1016\/j.diabres.2022.110187","article-title":"Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study","volume":"194","author":"J Kim","year":"2022","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"3","key":"pone.0294423.ref035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10620-015-3952-x","article-title":"Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record","volume":"61","author":"KE Corey","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"3","key":"pone.0294423.ref036","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00535-021-01759-2","article-title":"Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.","volume":"56","author":"S Terai","year":"2021","journal-title":"Journal of Gastroenterology"},{"issue":"5","key":"pone.0294423.ref037","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"AM Allen","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"pone.0294423.ref038","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/liv.13941","article-title":"Visceral adiposity index as a predictor of NAFLD: A prospective study with 4\u2010year follow\u2010up","volume":"38","author":"C Xu","year":"2018","journal-title":"Liver International"},{"issue":"5","key":"pone.0294423.ref039","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"S Zelber-Sagi","year":"2012","journal-title":"Journal of hepatology"},{"issue":"3","key":"pone.0294423.ref040","doi-asserted-by":"crossref","first-page":"e025806","DOI":"10.1136\/bmjopen-2018-025806","article-title":"Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study","volume":"9","author":"R Nishimura","year":"2019","journal-title":"BMJ Open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:33:05Z","timestamp":1700677985000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294423"}},"subtitle":[],"editor":[{"given":"Han Eol","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294423","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}